Skip to main content
Premium Trial:

Request an Annual Quote

Saskatchewan Disease Control Lab to Use Fluidigm BioMark in Infectious Disease Testing

Premium

Fluidigm said today that the Saskatchewan Disease Control Laboratory operated by the province's Ministry of Health will use the Fluidigm BioMark HD system as a "cornerstone" technology in its laboratory in Regina.

The SDCL provides a variety of services to the public health institutions in the province, including testing and monitoring of environmental specimens, food-borne illnesses, communicable diseases, and influenza, as well as a neonatal screening program.

The laboratory has developed a unique set of real-time PCR based tests to detect a wide range of respiratory and enteric diseases such as influenza, norovirus, and salmonella, and will use the tests in conjunction with the BioMark HD system to rapidly identify pathogens, Fluidigm said.

The BioMark HD system uses Fluidigm's microfluidic-based integrated fluidic circuits to quickly perform up to 9,216 tests in parallel within hours of receiving the sample from the clinic.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.